Modality
Vaccine
MOA
MALT1i
Target
PD-1
Pathway
Complement
Psoriasis
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
Phase 1Current
NCT03422110
814 pts·Psoriasis
2022-04→TBD·Terminated
814 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-059mo agoNDA· Psoriasis
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Termina…
Catalysts
NDA
2025-07-05 · 9mo ago
Psoriasis
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03422110 | Phase 1/2 | Psoriasis | Terminated | 814 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |